By simply eating four or more servings of green salad a week and working in the garden once or twice a week, smokers and nonsmokers alike may be able to substantially reduce the risk of developing lung cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.
10th December 2007 | 0 Comments
An international team of researchers has shown how mutations in the BRCA1 gene lead to breast cancer. Findings show that one way BRCA1 mutations cause cancer is by knocking out a powerful tumor suppressor gene known as PTEN.
10th December 2007 | 0 Comments
The next cancer-fighting therapeutic could be growing in your garden, according to research presented at the American Association for Cancer Research’s Sixth Annual International Conference on Frontiers in Cancer Prevention Research.
6th December 2007 | 0 Comments
A new model for calculating invasive breast cancer risk, called the CARE model, has been found to give better estimates of the number of breast cancers that would develop in African American women 50 to 79 years of age than an earlier model which was based primarily on data from white women. Both models were designed to be used by health care professionals and should either be used by them or in consultation with them. Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and their collaborators report on the study methodology and results online in JNCI.
5th December 2007 | 0 Comments
Researchers at the University of Michigan Comprehensive Cancer Center have found a marker that can be used to identify stem cells in breast tumors, suggesting a potential simple test that could help determine the best treatment for breast cancer.
3rd December 2007 | 0 Comments
The extra blood volume produced in the obese may so dilute levels of a telltale protein produced by prostates that the popular PSA test may be significantly less effective for diagnosing prostate cancer in men carrying extra pounds, a new study in The Journal of the American Medical Association suggests.
21st November 2007 | 0 Comments
The FDA has approved Bayer HealthCare AG’s drug, Nexavar (sorafenib) in patients with hepatocellular carcinoma when the cancer can not be removed surgically. Hepatocellular carcinoma is a type of liver cancer.
20th November 2007 | 0 Comments
Both study arms of a randomized, multi-center Phase II clinical study of Genentech’s drug, Avastin (bevacizumab), administered alone or in combination with irinotecan chemotherapy demonstrated encouraging 6-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer, according to the company.
19th November 2007 | 0 Comments
Two tiny genetic variations may provide the best clues yet for finding more precise ways to estimate prostate cancer risk and improve screening and early detection for men of African descent, report researchers from the University of Chicago and the Translational Genomics Research Institute, Phoenix, AZ, in the December 2007 issue of Genome Research, published early online.
3rd November 2007 | 0 Comments
It remains unclear whether PSA screening for prostate cancer reduces prostate cancer deaths, according to a study by the Veterans Affairs medical Center and Dartmouth researchers. While PSA (prostate-specific antigen) tests have become widely used to screen for prostate cancer, a biopsy is what actually determines the presence of prostate cancer.
Nearly a third of prostate biopsies resulted in a cancer diagnosis among a population of older men on Medicare, the investigators reported. Men whose first biopsy did not find cancer often had repeat biopsies later, which increased the chance of a cancer diagnosis in the future.
The researchers estimated the proportion of prostate biopsies that result in a cancer diagnosis and the likelihood of finding cancer with subsequent biopsies after the first one was negative. They analyzed the outcomes of 10,429 biopsies performed from 1993 to 2001 in 8,273 men aged 65 and older.
About one third of prostate biopsies detected cancer, and the proportion of biopsies that found cancer increased as men got older. Among men whose first biopsy did not show cancer, about one third of them had another biopsy within five years. Nearly half the men who had a second biopsy were diagnosed with cancer, and the chance of diagnosis increased with each subsequent biopsy.
“Because the goal of screening is to reduce deaths from the disease and not simply to find more cancer, the utility of [repeated biopsies warrant] careful reassessment,” the authors wrote.
The study was published in the September 19, 2007 Journal of the National Cancer Institute, and was led by Dr. H. Gilbert Welch of the Veterans Affairs Medical Center in White River Junction, VT, and professor of medicine and of community and family medicine at Dartmouth Medical School.
Source: Dartmouth Medical School
28th October 2007 | 0 Comments